Table 2 Descriptive results of socio demographic, treatment related and clinical characteristics of patients on second-line treatment in Amhara region (February 2008 – April 2016)
Variable | Total N (%) | Treatment failure | |
|---|---|---|---|
Failure N (%) | Censored N (%) | ||
Age | |||
15–24 | 105 (10.39) | 28 (11.02) | 77 (10.17) |
25–34 | 490 (54.08) | 124 (48.82) | 366 (48.35) |
35–44 | 299 (32.71) | 74(29.13) | 225 (29.72) |
≥ 45 | 117(10.37) | 28(11.02) | 89 (11.76) |
Gender | |||
Female | 498 (49.26) | 118 (46.46) | 380 (50.20) |
Male | 513 (50.74) | 136 (53.54) | 377 (49.80) |
BMI(kg/m2) | |||
< 18.5 | 395 (39.07) | 111 (43.70) | 409 (54.03) |
18.5–24.99 | 538 (53.21) | 129 (50.79) | 284 (37.52) |
> 25 | 78 (7.72) | 14 (5.51) | 64 (8.45) |
CD4 count at switch | |||
≥ 100 cells/mm3 | 400 (39.56) | 111(43.70) | 289 (38.18) |
< 100 cells/mm3 | 611(60.44) | 143 (56.30) | 468 (61.82) |
Regimen modification | |||
Yes | 435 (43.03) | 85 (33.46) | 350(46.24) |
No | 576 (56.97) | 169 (66.54) | 407(53.76) |
ART adherence | |||
Good | 462 (45.70) | 101 (39.76) | 361(47.69) |
Fair | 196 (19.39) | 43 (16.93) | 153 (20.21) |
Poor | 353 (34.92) | 110 (43.31) | 243 (32.10) |
WHO clinical stage | |||
I | 468 (46.29) | 114 (44.88) | 354 (46.76) |
II | 89 (8.80) | 20 (7.87) | 69 (9.11) |
III | 371 (36.70) | 84 (33.07) | 287(37.91) |
IV | 83 (8.21) | 36 (14.17) | 47 (6.21) |
INH given | |||
Yes | 277 (27.40) | 51(20.08) | 226 (29.85) |
No | 734 (72.60) | 203 (79.92) | 531(70.15) |
Functional status at switch | |||
Working | 856 (84.67) | 206 (83.74) | 650 (85.87) |
Ambulatory | 137 (13.55) | 40 (16.26) | 97 (12.81) |
bedridden | 18 (1.78) | 8 (3.25) | 10 (1.32) |
Opportunistic Infections (OI) | |||
Yes | 78 (7.72) | 18 (7.09) | 60 (7.93) |
No | 933 (92.28) | 236 (92.91) | 697 (92.07) |
Second-line regimen | |||
ABC-ddI-LPV/r | 189 (18.69) | 35 (13.78) | 154 (20.34) |
TDF-3TC-LPV/r | 351 (34.72) | 94 (37.01) | 257(33.95) |
AZT-3TC-LPV/r | 106 (10.48) | 37 (14.57) | 69 (9.11) |
Othersa | 365 (36.10) | 88 (34.65) | 277(36.59) |